证券代码：002137 证券简称：实益达 公告编号：2026-003 深圳市实益达科技股份有限公司 关于使用自有闲置资金进行现金管理的进展公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 深圳市实益达科技股份有限公司（以下简称"公司"）于2025年8月15日召 开了第七届董事会第十一次会议审议通过了《关于使用部分自有闲置资金进行现 金管理的议案》，并于2025年9月4日召开2025年第二次临时股东会审议通过该议 案，为提高公司自有资金使用效率，在不影响公司正常经营及业务发展的情况下， 为进一步拓宽资金投资渠道，增加投资收益，同意公司任一时点使用部分自有闲 置资金最高不超过人民币100,000万元进行现金管理，有效期为股东会审议通过 之日起12个月；资金可在上述额度内滚动使用，在额度范围内由董事会授权公司 董事长行使该项投资决策权并签署相关合同，具体投资活动由公司及子公司财务 负责人组织实施。具体内容详见公司刊登于2025年8月19日《证券时报》及巨潮 资讯网(www.cninfo.com.cn)的《关于使用部分自有闲置资金进行现金管理的公 告》。 现将公司近期使 ...

创业板指缩量涨超1%，沪指跌近1%，算力硬件概念集体走强、有色板块30余股跌停。湖南黄金5连板，百川股份3连板，一图看懂>> 公司与中国科学院空间应用工程与技术中心开展合作,相关产品应用于"中国空间 站"在轨实验，与中国商飞旗下上海飞机制造有限公司开展合作，公司相关产品已应用 于"C919大飞机"项目,均获得客户高度评价 长江通信 低轨卫星通信是公司重点开拓的新行业之一,公司背靠中国信科,其在星地融合标准制 定上发挥了突出的贡献,自R18开始首次实现中国在3GPPNTN的标准立项,目前已累 计牵头16项,是全球牵头卫星NTN立项最多的公司 天通股份 1、子公司天通精电应邀参加中国空天信息和卫星互联网创新联盟大会,展示商业卫星 数字化批量电装技术,助力国家空天信息产业供应链建设;2、公司生产的银酸锂晶体 材料是锟酸锂电光调制芯片及器件的上游关键原材料; 3、子公司天通精电为全球知名 电子品牌客户提供PCB及一站式电子制造服务,延伸产业链至电子部品和整机制造 石油化工 百川股份 3天3板 1、公司从事醋酸酯类、偏苯三酸酐及酯类等化工产品的研产销;2、公司积极布局锂 电材料产业链,构建起磷酸铁/针状焦→磷酸铁锂/石 ...

证券日报网讯1月26日，实益达（002137）在互动平台回答投资者提问时表示，关于公司2025年度业绩 预告详情请参阅公司于2026年1月23日在《证券时报》以及巨潮资讯网披露的《2025年度业绩预告》， 公司2025年度经营业绩的具体情况以公司后续正式披露的《2025年年度报告》为准。关于参股公司的具 体信息请以其官网公布信息为准。 ...

Group 1: Company Fundraising and Investment - Company plans to use 500 million yuan of raised funds to increase capital in its wholly-owned subsidiaries for the implementation of a DRAM investment project [1] - Zhuhai Hengqin Chip Storage Co., Ltd. will receive 30 million yuan, and Hefei Chip Storage Co., Ltd. and Xi'an Chip Storage Co., Ltd. will receive 50 million yuan and 30 million yuan respectively for the DRAM project [1] Group 2: Profit Forecasts and Turnarounds - Yiling Pharmaceutical expects a net profit of 1.2 billion to 1.3 billion yuan in 2025, recovering from a loss of 725 million yuan in the previous year [2] - Liard anticipates a net profit of 300 million to 380 million yuan in 2025, compared to a loss of 889 million yuan last year, driven by a new strategic cycle focusing on AI [2] - Daming City forecasts a net profit of 140 million to 165 million yuan in 2025, recovering from a loss in the previous year, aided by reduced asset impairment losses [3] - Guanghua Technology expects a net profit of 85 million to 120 million yuan in 2025, recovering from a loss of 205 million yuan last year, due to expansion in specialized chemicals and PCB sectors [3] - Boteng Co. anticipates a net profit of 80 million to 105 million yuan in 2025, recovering from a loss of 288 million yuan, supported by operational efficiency improvements [4] - Shiyida expects a net profit of 31 million to 46 million yuan in 2025, recovering from a loss of 2.34 million yuan last year, driven by business development and cost control [4] - Guochuang High-tech forecasts a net profit of 16 million to 24 million yuan in 2025, recovering from a loss of 49 million yuan, aided by improved receivables management [5][6] Group 3: Share Buybacks - Hengyi Petrochemical plans to repurchase shares with a total fund of no less than 500 million yuan and no more than 1 billion yuan, with a maximum price of 15 yuan per share [7] - Yunyi Electric plans to repurchase shares with a total fund of no less than 100 million yuan and no more than 150 million yuan, with a maximum price of 17 yuan per share [7] - Xidian Pharmaceutical intends to repurchase shares with a total fund of no less than 25 million yuan and no more than 50 million yuan, with a maximum price of 42 yuan per share [7] Group 4: Performance Highlights - Te Yi Pharmaceutical expects a net profit of 70 million to 90 million yuan in 2025, a growth of 241.55% to 339.13% year-on-year [8] - Xingqi Eye Medicine anticipates a net profit of 662 million to 749 million yuan in 2025, a growth of 95.82% to 121.56% year-on-year [8] - Tianhe Co. forecasts a net profit of 41 million to 60 million yuan in 2025, a growth of 84.35% to 169.78% year-on-year [8] - Ruichuang Micro-Nano expects a net profit of approximately 1.1 billion yuan in 2025, a 93% increase year-on-year [9] - Zhongyuan Co. anticipates a net profit of 139 million to 158 million yuan in 2025, a growth of 80% to 105% year-on-year [9] Group 5: Important Corporate Developments - Aolaide has received acceptance for its application to issue securities on the Science and Technology Innovation Board [14] - *ST Songfa's subsidiary signed contracts for the construction of two VLCC super-large oil tankers, expected to positively impact future performance [15] - Chongda Technology's subsidiary signed an investment agreement for a 1 billion yuan IC packaging project in Jiangsu Province [15] - Yinglian Co. signed a strategic agreement with LG Chem to establish a joint laboratory for innovative materials in lithium battery applications [16]

Core Viewpoint - The company Shiyida (002137.SZ) has announced its earnings forecast for the year 2025, projecting a net profit attributable to shareholders of between 31 million and 46 million yuan, indicating a turnaround from losses to profits [1] Financial Performance - The net profit after deducting non-recurring gains and losses is expected to be between 20 million and 30 million yuan, representing a year-on-year growth of 78.16% to 167.24% [1]

Group 1 - Huakang Clean announced it is the first candidate for the bid of the Wuhan First Hospital expansion project with a bid amount of 54.88 million yuan and a construction period of 120 days [1] - Hualing Steel's subsidiary plans to invest 449.88 million yuan in a major overhaul project for its coking plant, aiming to address aging issues and restore production capacity over a 19-month construction period [2] - Yinjia Technology expects a net loss of 140 million to 110 million yuan for 2025, compared to a loss of 129 million yuan in the previous year [3] Group 2 - Guochuang High-tech forecasts a net profit of 16 million to 24 million yuan for 2025, recovering from a loss of 58.52 million yuan in the previous year [4] - Shiyi Da anticipates a net profit increase of 31 million to 46 million yuan for 2025, turning around from a loss of 23.41 million yuan last year [5] - Lijun Co. expects a net profit of 48 million to 66 million yuan for 2025, representing a decline of 45.05% to 60.03% compared to the previous year [7] Group 3 - Xindian Pharmaceutical plans to repurchase shares worth 25 million to 50 million yuan for employee stock ownership plans or equity incentives, with a maximum repurchase price of 42 yuan per share [6] - Jingchen Co. has set the initial transfer price for its shares at 82.85 yuan per share, with a total of 13.1 million shares to be transferred to 28 institutional investors [8] - Zejing Pharmaceutical received approval for clinical trials of its innovative cancer immunotherapy drug ZG005 in combination with platinum-based chemotherapy for advanced nasopharyngeal and esophageal squamous cell carcinoma [9] Group 4 - Xingqi Eye Medicine expects a net profit of 662 million to 749 million yuan for 2025, marking a growth of 95.82% to 121.56% compared to the previous year [10] - Liancheng Precision anticipates a net loss of 12 million to 17 million yuan for 2025, reducing its loss from 37.96 million yuan in the previous year [11] - Beidou Star expects a net loss of 230 million to 290 million yuan for 2025, improving from a loss of 350 million yuan last year [13] Group 5 - Qing Shan Paper's affiliate won a bid for a wastewater treatment project worth 51.9 million yuan [15] - Yiling Pharmaceutical forecasts a net profit of 1.2 billion to 1.3 billion yuan for 2025, recovering from a loss of 725 million yuan in the previous year [16] - Huahai Pharmaceutical received a drug registration certificate for its product used in treating depression and obsessive-compulsive disorder [23] Group 6 - Nanjing Panda expects a net profit of 10 million to 15 million yuan for 2025, turning around from a loss of 189 million yuan last year [40] - Rui Sheng Intelligent anticipates a net profit of 33.92 million to 38.40 million yuan for 2025, representing a growth of 112% to 140% compared to the previous year [41] - Jiechang Drive expects a net profit of 395 million to 437 million yuan for 2025, with a growth of 40% to 55% compared to the previous year [43]

Core Viewpoint - The company Shiyida (002137) expects a significant turnaround in its financial performance, projecting a net profit attributable to shareholders of 31 to 46 million yuan for 2025, compared to a loss of 23.41 million yuan in the same period last year [1]. Group 1 - The company is focusing on its core business development and steadily advancing various business operations [1]. - The company is actively expanding both domestic and international markets [1]. - The company is implementing cost-saving measures and efficiency improvements to provide more value-added services to customers [1].

Core Viewpoint - The company expects significant growth in net profit for the year 2025, with projections indicating an increase of 232.44% to 296.52% compared to the previous year [1] Financial Performance - The estimated net profit attributable to shareholders for 2025 is projected to be between 31 million and 46 million yuan [1] - The estimated net profit after deducting non-recurring gains and losses is expected to be between 20 million and 30 million yuan, reflecting a year-on-year increase of 78.16% to 167.24% [1] Business Strategy - The company has focused on its core business development, steadily advancing various operations, and actively exploring domestic and international markets [1] - Efforts to enhance efficiency and reduce costs have been implemented, allowing the company to provide more value-added services to customers [1] Non-recurring Gains and Losses - The increase in non-recurring gains and losses is attributed to a significant loss from the fair value change of an associate company in the previous year, amounting to 49.735 million yuan [1] - The overall impact of fair value changes from associate companies on profits during the current reporting period is expected to be minimal [1]

Core Viewpoint - The company expects to achieve a net profit attributable to shareholders of 31 million to 46 million yuan in 2025, marking a turnaround from losses, with a significant increase in net profit excluding non-recurring gains and losses [1] Financial Performance - The projected net profit for 2025 is expected to grow by 232.44% to 296.52% compared to the same period last year [1] - The net profit excluding non-recurring gains and losses is anticipated to be between 20 million and 30 million yuan, reflecting a year-on-year growth of 78.16% to 167.24% [1] Strategic Focus - The company is focusing on its core business development and steadily advancing various business operations [1] - Efforts to expand both domestic and international markets are being actively pursued [1] - The company is implementing cost-saving measures and enhancing efficiency to provide more value-added services to customers [1]

Core Viewpoint - The company expects a significant turnaround in its financial performance for the fiscal year 2025, projecting a net profit attributable to shareholders between 31 million and 46 million yuan, marking a substantial increase compared to a loss of 23.41 million yuan in the previous year, representing a growth of 232.44% to 296.52% [1] Financial Performance - The anticipated net profit for 2025 is projected to be between 31 million and 46 million yuan, indicating a strong recovery from the previous year's loss [1] - The expected net profit after deducting non-recurring items is estimated to be between 20 million and 30 million yuan, reflecting a year-on-year growth of 78.16% to 167.24% [1] Factors Contributing to Growth - The company's performance improvement is attributed to a focus on its core business, market expansion, and cost reduction efforts [1] - An increase in non-recurring gains during the current period has also contributed to the anticipated financial results [1]